Once‐daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double‐blind, placebo‐controlled study
The DOI matches its Crossref record.
Abstract
Abstract Background Chronic idiopathic urticaria (CIU) is the most common type of chronic urticaria, and pruritus is the most prominent symptom. Antihistamines are the first‐line treatment for CIU. Sedation and anticholinergic adverse effects are often experienced with the first‐generation antihistamines and there is a risk of cardiovascular adverse effects and drug interactions with some second‐generation agents. Hence, new treatment options are needed. Desloratadine is a new, potent, nonsedating antihistamine that has an excellent cardiovascular safety profile. Methods This was a multicenter, randomized, double‐blind, placebo‐controlled study designed to determine the efficacy and safety of desloratadine in the treatment of moderate‐to‐severe CIU. A total of 190 patients, aged 12–79 years, with at least a 6‐week history of CIU and who were currently experiencing a flare of at least moderate severity, were randomly assigned to therapy with desloratadine 5 mg or placebo once daily for 6 weeks. Twice daily, patients rated the severity of CIU symptoms (pruritus, number of hives, and size of largest hive), as well as the impact of CIU symptoms on sleep and daily activity. Patients and investigators jointly evaluated therapeutic response and overall condition. Safety evaluations included the incidence of treatment‐emergent adverse events, discontinuations due to adverse events, and changes from baseline in vital signs, laboratory parameters, and ECG intervals. Results Desloratadine was superior to placebo in controlling pruritus and total symptoms after the first dose and maintained this superiority to the end of the study. Measures of sleep, daily activity, therapeutic response, and global CIU status were also significantly better with desloratadine after the first dose; these clinical benefits were also maintained throughout the 6‐week study. No significant adverse events occured. Conclusions Desloratadine 5 mg daily is a safe and effective treatment for CIU with significant benefits within 24 h and maintained through the treatment period.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Maurer, M., Weller, K., Bindslev-Jensen, C., Giménez-Arnau, A., Bousquet, P. J., Bousquet, J., Canonica, G. W., Church, M. K., Godse, K. V., Grattan, C. E. H., et al. (2011) · Allergy · doi:10.1111/j.1398-9995.2010.02496.x · Cited by 843
EAACI/GA²LEN/EDF/WAO guideline: management of urticaria
Zuberbier, T., Asero, R., Bindslev‐Jensen, C., Walter Canonica, G., Church, M. K., Giménez‐Arnau, A. M., Grattan, C. E. H., Kapp, A., Maurer, M., Merk, H. F., et al. (2009) · Allergy · doi:10.1111/j.1398-9995.2009.02178.x · Cited by 527
EAACI/GA2LEN/EDF guideline: management of urticaria
Zuberbier, T., Bindslev‐Jensen, C., Canonica, W., Grattan, C. E. H., Greaves, M. W., Henz, B. M., Kapp, A., Kozel, M. M. A., Maurer, M., Merk, H. F., et al. (2006) · Allergy · doi:10.1111/j.1398-9995.2005.00962.x · Cited by 461
BSACI guideline for the management of chronic urticaria and angioedema
Powell, R. J., Leech, S. C., Till, S., Huber, P. A. J., Nasser, S. M., & Clark, A. T. (2015) · Clinical & Experimental Allergy · doi:10.1111/cea.12494 · Cited by 377
Second-Generation Antihistamines: Actions and Efficacy in the Management of Allergic Disorders
Golightly, L. K., & Greos, L. S. (2005) · Drugs · doi:10.2165/00003495-200565030-00004 · Cited by 111
Metadata
- Authors
- Ring, J., Hein, R., Gauger, A., Bronsky, E., Miller, B., & and the Desloratadine Study Group
- Venue
- International Journal of Dermatology
- Publisher
- Wiley
- Published
- 2001-01
- Volume
- 40
- Issue
- 1
- Pages
- 72-76
- ISSN
- 0011-9059 (ISSN-L)
- 1365-4632
- OpenAlex
- W2083666610
- Cited by
- 130
- References
- 0
- FWCI
- 7.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Once‐daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double‐blind, placebo‐controlled study. https://app.cochat.ai/papers/10.1046/j.1365-4362.2001.00186.x
- The paper
- Ring, J., Hein, R., Gauger, A., Bronsky, E., Miller, B., & and the Desloratadine Study Group. (2001). Once‐daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double‐blind, placebo‐controlled study. International Journal of Dermatology. https://doi.org/10.1046/j.1365-4362.2001.00186.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.